close

KILL Legend Biotech Announces Submission of New Drug Application to Japanese Regulatory Authority for BCMA CAR-T Therapy Cilta-cel for the Treatment of Relapsed or Refractory Multiple Myeloma by Janssen

ⓘ This article is third-party content and does not represent the views of this site. We make no guarantees regarding its accuracy or completeness.

 

Legend Biotech requests that their press release NewsItemId: 20211206005107 “Legend Biotech Announces Submission of New Drug Application to Japanese Regulatory Authority for BCMA CAR-T Therapy Cilta-cel for the Treatment of Relapsed or Refractory Multiple Myeloma by Janssen” be killed.

The release was issued prematurely by Legend Biotech. The release will be reissued at a later date.

Contacts

Report this content

If you believe this article contains misleading, harmful, or spam content, please let us know.

Report this article

More News

View More

Recent Quotes

View More
Symbol Price Change (%)
AMZN  254.16
-3.21 (-1.25%)
AAPL  347.62
-1.58 (-0.45%)
AMD  443.00
-46.19 (-9.44%)
BAC  48.14
-0.43 (-0.89%)
GOOG  273.63
+2.62 (0.96%)
META  575.32
-20.90 (-3.51%)
MSFT  491.61
-6.69 (-1.34%)
NVDA  137.11
-8.87 (-6.08%)
ORCL  104.22
-6.35 (-5.74%)
TSLA  361.60
-12.81 (-3.42%)
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

Starting at /week.